Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 9, 2013, Pages

  Derry, Sheena ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METOCLOPRAMIDE; PARACETAMOL; PLACEBO; SUMATRIPTAN; ANALGESIC AGENT; ANTIEMETIC AGENT;

ADULT; ANALGESIA; COMBINATION DRUG THERAPY; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; PAIN INTENSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THORAX PAIN; ACUTE DISEASE; DRUG COMBINATION; LOUDNESS RECRUITMENT; META ANALYSIS; METHODOLOGY; PHOTOPHOBIA;

ACETAMINOPHEN; ACUTE DISEASE; ADULT; ANALGESICS, NON-NARCOTIC; ANTIEMETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERACUSIS; METOCLOPRAMIDE; MIGRAINE DISORDERS; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUMATRIPTAN;

EID: 84886814195     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008040.pub3     Document Type: Review

References (77)

1. Dexter SL, Graham AN, Johnston ES, Ratcliffe DM, Wilkinson MI, Rose AJ. Double-blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice 1985;39(10):388-92. 2624506
2. Dowson A, Ball K, Haworth D. Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion 2000;16(3):190-7. 2624508
3. Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008;48(6):921-30. [DOI: 10.1111/j.1526-4610.2007.01053.x]2624510
4. A double-blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk-clinicalstudyregister.com/. 2624512
5. A double-blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk-clinicalstudyregister.com/. 2624514
6. Hoernecke R, Doenicke A. Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich) 1993;88(11):642-8. 2624516
7. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double-blind, placebo-controlled, population-based study. Archives of Internal Medicine 2000;160(22):3486-92. 2624518
8. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993;13(2):124-7. 2624520
9. Nørrelund N, Christiansen LV, Plantener S. Tolfenamic acid versus paracetamol in migraine attacks. A double-blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger 1989;151(38):2436-8. 2624522
10. Oztürk V, Ertaş M, Baykan B, Sirin H, Ozge A, The Mig-Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1, 000 mg paracetamol in acute treatment of migraine: a randomized, double-blind, crossover, multicenter, phase III clinical trial. Pain Practice 2012:Epub ahead of print. [DOI: 10.1111/j.1533-2500.2012.00572.x]2624524
11. Prior MJ, Codispoti JR, Fu M. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache 2010;50(5):819-33. [DOI: 10.1111/j.1526-4610.2010.01638.x]2624526
12. Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double-blind, crossover trial. Headache 1976;15(4):282-7. 2624528
13. Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005;25(10):776-87. [DOI: 10.1111/j.1468-2982.2005.00948.x]2624530
14. Larsen BH, Christiansen LV, Andersen B, Olesen J. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurologica Scandinavica 1990;81(5):464-7. 2624532
15. Ad Hoc Committee on the Classification of Headache, National Institute of Neurological Diseases and Blindness. Classification of headache. JAMA 1962;179(9):717-8.
16. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 2012;32(5):373-81. [DOI: 10.1177/0333102412438977]
17. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559-66. [DOI: 10.1212/01.wnl.0000323925.29520.e7]
18. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain 2012;13(5):361-78. [DOI: 10.1007/s10194-012-0460-7]
19. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases 2000;31(5):S203-S210.
20. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2012;52(1):3-17. [DOI: 10.1111/j.1526-4610.2011.02046.x]
21. Chandrasekharan NV. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proceedings of the National Academy of Sciences of the United States of America 2002;99(21):13926-31.
22. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1-2):95-7. [DOI: 10.1016/S0304-3959(97)00005-5]
23. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
24. Committee on Safety of Medicines. Medicines Control Agency. Paracetamol and aspirin. Current Problems in Pharmacovigilance 1997;23:9.
25. Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. American Journal of Medicine 2000;7(2):123-34.
26. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008615.pub2]
27. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008783.pub3]
28. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63. [DOI: 10.1111/j.1526-4610.2006.00631.x]
29. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998;56(5):811-24.
30. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140]
31. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. European Journal of Neurology 2009;16(9):968-81. [DOI: 10.1111/j.1468-1331.2009.02748.x]
32. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240(5381):410-1.
33. Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005;64(3):463-8. [DOI: 10.1212/01.WNL.0000150904.28131.DD]
34. Graham GG, Scott KF. Mechanism of action of paracetamol. American Journal of Therapeutics 2005;12(1):46-55. [DOI: 10.1097/00045391-200501000-00008]
35. Gunnell D, Hawton K, Garnier V, Bismuth C, Fagg J. Use of paracetamol for suicide and non-fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health 1997;51(2):175-9.
36. Hawkins LC, Edwards JN, Dargan PI. Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature. Drug Safety 2007;30(6):465-79.
37. Hawton K, Townsend E, Deeks J, Appleby L, Gunnell D, Bennewith O, et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ 2001;322(7296):1203-7.
38. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health 2009;12(1):55-64. [DOI: 10.1111/j.1524-4733.2008.00404.x]
39. Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. Federation of American Societies for Experimental Biology Journal 2008;22(2):383-90. [DOI: 10.1096/fj.07-8506com]
41. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96.
42. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20(9):765-86.
43. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:1-160.
44. Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66(2-3):239-46.
45. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
46. Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008041.pub3]
47. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
48. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain 2005;6(6):429-40. [DOI: 10.1007/s10194-005-0252-4]
49. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology 2012;19(5):703-11. [DOI: 10.1111/j.1468-1331.2011.03612.x]
50. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 1999;39 Suppl 2:S20-S26.
51. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9.
52. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46(5):715-25. [DOI: 10.1111/j.1526-4610.2006.00430.x]
53. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
54. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
55. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with confidence - confidence intervals and statistical guidelines. London: British Medical Journal, 1995:50-63.
56. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009;49(4):498-508. [DOI: 10.1111/j.1526-4610.2009.01369.x]
57. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Current Opinion in Gastroenterology 2008;24(3):287-97.
58. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-57. [DOI: 10.1016/S0304-3959(02)00024-6]
59. PharmWeb. Paracetamol Information Centre. www.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 30 July 2009).
60. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction?. American Journal of Therapeutics 2000;7(2):99-114.
61. Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008039.pub2]
62. Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache 2009;49(1):79-89. [DOI: 10.1111/j.1526-4610.2008.01263.x]
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
64. Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. European Journal of Clinical Pharmacology 1983;24(6):777-85.
65. Salazar-Tortolero G, Huertas-Campistol A, Vergez-Pinto L, Ramos-Brunet A, Lluch-López J. Metoclopramide as a painkiller for intense migraine headache in emergency departments [Metoclopramida como analgésicoen la cefalea migrañosa intensa en urgencias]. Revista de Neurologia 2008;47(10):506-8.
66. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol?. Lancet 2003;361(9362):981-2.
67. Soyka D. Diagnosis of migraine [Diagnostik der Migrane]. Deutsche Medizinische Wochenschrift 1988;113(18):735-6.
68. Steiner TS, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Journal of Headache and Pain 2013;14:1. [DOI: 10.1186/1129-2377-14-1]
69. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain 2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0]
70. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate results on meta-analysis: a case study. BMJ 1997;315(7109):635-9.
71. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30(9):1065-72.
72. Volans GN. Absorption of effervescent aspirin during migraine. British Medical Journal 1974;4(5939):265-8.
73. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. British Journal of Clinical Pharmacology 1975;2(1):57-63.
74. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 1016/S0140-6736(12)61729-2]
75. Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy 2003;23(4):494-505.
76. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 2012;52(4):582-91. [DOI: 10.1111/j.1526-4610.2011.02061.x]
77. Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD008040.pub2]